177Lu-PSMA放射性药物治疗期间治疗后显像的进展模式
该回顾性多中心研究分析了361例接受至少2周期[177Lu]Lu-PSMA RPT的患者,通过系列治疗后SPECT/CT和PSMA PET显像评估应答与进展模式。80%患者病灶缩小或减少,43%出现进展,新发骨病灶中67%为PSMA低摄取,PSMA阴性进展少见且多早期出现,PSA与影像不一致率25%-43%。
要点
- 治疗后显像示80%患者病灶缩小或减少,43%在治疗期间进展。
- 新发骨病灶常见,其中67%为PSMA低摄取病变。
- PSA与影像进展不一致率25%-43%,需整合影像评估。
核心结论
- 177Lu-PSMA RPT期间进展最常发生于骨,67%新发骨病灶患者存在PSMA低摄取病变。
- PSMA阴性进展不常见且倾向于早期出现。
- PSA与影像不一致常见,强调治疗全程需整合影像评估。
研究设计与样本
- 回顾性分析2个学术中心361例在2017年5月至2025年3月间接受至少2周期[177Lu]Lu-PSMA RPT的患者。
- 治疗后SPECT/CT定性评估应答和进展部位与模式,包括PSMA低摄取和PSMA阴性病变。
- 进展定义为SPECT/CT上新发病灶或原有病灶至少2倍增大。
主要发现
- 290/361(80%)患者治疗后显像病灶大小或数量减少。
- 312例基线骨病患者中81%治疗后显像应答。
- 156/361(43%)患者治疗期间进展,132例新发骨病灶,其中89例(67%)为PSMA低摄取病变。
- 第2周期新发病灶64%为骨,至第4-6周期增至至少90%。
- PSMA阴性进展22例(6%),主要位于肝(11例)和淋巴结(8例),59%在第2周期检测到。
关键数值与推荐
- PSA应答按PCWG3标准定义为较基线下降至少50%。
- 进展定义为SPECT/CT新发病灶或原有病灶至少2倍增大。
- 81例治疗完成或暂停后PSA进展且有影像者中,74例(91%)影像进展,其中69例(93%)骨进展、13例(18%)淋巴结进展。
- PSA与影像不一致率跨周期为25%-43%,从第2周期至第6周期增加。
临床怎么用
- 治疗期间应结合系列治疗后SPECT/CT和PSMA PET评估应答与进展,不应仅依赖PSA。
- 关注骨病灶新发或增大,尤其PSMA低摄取成分。
- PSMA阴性进展虽少见但多早期出现,需在早期 cycle 警惕肝和淋巴结病变。
局限性
- 回顾性设计。
- 仅纳入2个学术中心患者。
- 进展定义基于SPECT/CT定性评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We characterized patterns of treatment response and progression during [177Lu]Lu-PSMA radiopharmaceutical therapy (RPT) using serial posttreatment SPECT/CT and prostate-specific membrane antigen (PSMA) PET imaging and evaluated cycle-by-cycle prostate-specific antigen (PSA)-imaging concordance. Methods: We retrospectively analyzed 361 patients from 2 academic centers who received at least 2 cycles of [177Lu]Lu-PSMA RPT between May 2017 and March 2025. Posttreatment SPECT/CT scans were qualitatively evaluated to determine the site and pattern of response and progression, including PSMA low-avidity and PSMA-negative disease. Progression was defined by the appearance of new lesions or at least a 2-fold growth in preexisting lesions on SPECT/CT. PSA response was defined per Prostate Cancer Clinical Trials Working Group 3 criteria as at least a 50% decline from baseline. For cycle-by-cycle concordance analysis, PSA change was classified directionally as rising or falling relative to the prior cycle. In patients who paused or completed RPT after response, progression imaging was compared with the final on-treatment SPECT/CT scan. Results: Overall, 290 of 361 (80%) patients demonstrated a decrease in lesion size or number on posttreatment imaging. Of 312 patients with baseline bone disease, 81% demonstrated a response on posttreatment imaging. In total, 156 of 361 patients (43%) demonstrated progression during treatment. New osseous lesions developed in 132 patients, of whom 89 (67%) had PSMA low-avidity disease. At cycle 2, 64% of new lesions were osseous, increasing to at least 90% by cycles 4-6. PSMA-negative progression occurred in 22 patients (6%), predominantly in the liver (n = 11) and lymph nodes (n = 8), with 59% detected at cycle 2. Among 81 patients with imaging available at PSA progression after treatment completion or pause, 74 (91%) had imaging progression; of these, 69 (93%) demonstrated osseous and 13 (18%) nodal progression. PSA and imaging were discordant in 25%-43% of patients across cycles, with discordance increasing from cycle 2 to cycle 6. Conclusion: Progression during [177Lu]Lu-PSMA RPT occurs most frequently in bone, with 67% of patients with new osseous lesions demonstrating a PSMA low-avidity disease component. PSMA-negative progression is uncommon and tends to emerge early. PSA-imaging discordance is frequent, underscoring the need for integrated imaging assessment throughout treatment.
引用
- Yadav, Khan, Moradi Tuchayi, et al. Patterns of Progression on Posttreatment Imaging During [177Lu]Lu-PSMA Radiopharmaceutical Therapy. J Nucl Med. 2026. PMID: 42957211. doi:10.2967/jnumed.126.272228
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。